Pharmacologic considerations for therapeutic success with antiretroviral agents.
about
Human inter-individual variability in metabolism and genotoxic response to zidovudineLamivudine Concentration in Hair and Prediction of Virologic Failure and Drug Resistance among HIV Patients Receiving Free ART in ChinaInfluence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAARTPharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.Determinants of individual variation in intracellular accumulation of anti-HIV nucleoside analog metabolites.Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents.Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors.Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.P-glycoprotein expression by peripheral blood mononuclear cells from human immunodeficiency virus-infected patients is independent from response to highly active antiretroviral therapy.Nelfinavir suspension obtained from nelfinavir tablets has equivalent pharmacokinetic profile.Development of a population simulation model for HIV monotherapy virological outcomes using lamivudine.Can Urine Lamivudine Be Used to Monitor Antiretroviral Treatment Adherence?Identification of key mutations in HIV reverse transcriptase gene can influence the clinical outcome of HAART.
P2860
Q23918962-9DBC344A-90AD-429A-8CFF-14E72CA9F2B8Q28551633-5BE10DF1-FFEA-41DC-BE6D-F527FA91EECDQ34012749-ABD56254-6EEC-47DB-B4AE-D821140CA51FQ34113462-EF3D9F49-57B7-4EB5-8F26-71C73216736FQ34529268-EB5FA286-EE1A-48CB-81A1-0F0D5C9D3296Q34973688-D865DFF9-0AC6-4ECA-BB57-AF63F357B903Q36727960-809D0C2D-E517-43E5-9DEB-CEB49DC11184Q37489345-C0D9A922-9A33-4BB1-9BD0-1997697F0907Q42625394-6349570D-F42F-448B-8622-320D4D648FBEQ42845454-26093CA7-390E-4DD6-A1DD-CBAE878F9DC8Q43836005-D4E60B4C-C73C-4548-96F1-C1E78021EA0EQ45090413-0F438207-7D13-42B0-9407-4D1D72CBC752Q46043302-581A8BDE-D29E-410F-80F4-90F55433C844Q54003890-324D1F38-6A86-4448-BEF6-E6BF2EA7F640
P2860
Pharmacologic considerations for therapeutic success with antiretroviral agents.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Pharmacologic considerations for therapeutic success with antiretroviral agents.
@ast
Pharmacologic considerations for therapeutic success with antiretroviral agents.
@en
type
label
Pharmacologic considerations for therapeutic success with antiretroviral agents.
@ast
Pharmacologic considerations for therapeutic success with antiretroviral agents.
@en
prefLabel
Pharmacologic considerations for therapeutic success with antiretroviral agents.
@ast
Pharmacologic considerations for therapeutic success with antiretroviral agents.
@en
P2860
P356
P1476
Pharmacologic considerations for therapeutic success with antiretroviral agents.
@en
P2093
C V Fletcher
P2860
P304
P356
10.1345/APH.19075
P407
P577
1999-09-01T00:00:00Z